Tinengotinib in patients with advanced solid tumors harboring actionable FGFR1-3 mutations

被引：0
|
作者：
Piha-Paul, Sarina A.
Liao, Chih-Yi Andy
Fonkoua, Lionel
Mahipa, Amit, I
Goel, Sanjay
Fountzilas, Christos
Shen, Lin
Li, Daneng
Deming, Dustin
Dayyani, Farshid
Han, Weiqing
Niu, Zuoxing
Fan, Jean
Peng, Peng
Wang, Hui
Huang, Peng
Wu, Frank
Javle, Milind
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB162
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.
    Javle, Milind M.
    Fountzilas, Christos
    Li, Daneng
    Fonkoua, Lionel Aurelien Kankeu
    Fan, Jean
    Peng, Peng
    Wang, Hui
    Ngo, Brenda
    Sun, Caixia
    Ru, Qinhua Cindy
    Wu, Frank
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 539 - 539
  • [2] Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.
    Javle, Milind M.
    Mahipal, Amit
    Fonkoua, Lionel Aurelien Kankeu
    Fountzilas, Christos
    Li, Daneng
    Pelster, Meredith
    Liao, Chih-Yi
    Richards, Donald A.
    Deming, Dustin A.
    Younes, Mohamad Ahmad
    Mantry, Parvez
    Cohn, Allen Lee
    Kingsley, Ed
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Shan, Yujun
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 434 - 434
  • [3] Molecular testing for TWIST and FGFR1-3 mutations in a cohort of 153 craniofacial patients.
    Turner, AM
    Roscioli, T
    Elakis, G
    Taylor, PJ
    Cox, T
    Haan, E
    Oley, C
    McGaughran, J
    Dixon, J
    Edwards, M
    Savarirayan, R
    Gianoutsos, M
    David, DJ
    Buckley, MF
    Pospisil, V
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 212 - 212
  • [4] Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations
    Zhu, Wei
    Baig, Mahadi
    Naini, Vahid
    De Meulder, Marc
    Akapame, Sydney
    De Zwart, Loeckie
    Haddish-Berhane, Nahor
    Triantos, Spyros
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (10): : 1164 - 1176
  • [5] Targeting the FGFR Pathway in Patients with Advanced Solid Tumors
    Chehade, Chadi Hage
    Ozay, Zeynep Irem
    Agarwal, Neeraj
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4549 - 4551
  • [6] Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
    Meric-Bernstam, Funda
    Bahleda, Rastislav
    Hierro, Cinta
    Sanson, Marc
    Bridgewater, John
    Arkenau, Hendrik-Tobias
    Tran, Ben
    Kelley, Robin Kate
    Park, Joon Oh
    Javle, Milind
    He, Yaohua
    Benhadji, Karim A.
    Goyal, Lipika
    CANCER DISCOVERY, 2022, 12 (02) : 402 - 415
  • [7] Identification and validation of actionable mutations in solid tumors
    Zessin, Amelia S.
    Randall, Adrian
    McCall, Shannon
    Datto, Michael B.
    Hsu, Shiaowen David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Mutation Analysis of FGFR1-3 in 11 Japanese Patients with Syndromic Craniosynostoses
    Ohishi, Akira
    Nishimura, Gen
    Kato, Fumiko
    Ono, Hiroyuki
    Maruwaka, Kaori
    Ago, Mako
    Suzumura, Hiroshi
    Hirose, Etsuko
    Uchida, Yuki
    Fukami, Maki
    Ogata, Tsutomu
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2017, 173 (01) : 157 - 162
  • [9] Tinengotinib, a novel fibroblast growth factor receptor (FGFR) inhibitor, is potent against resistance mutations in FGFR1/2/3
    Qiang, Xiaoyan
    Yu, Qi
    Fan, Jean
    Wu, Frank
    Sun, Caixia
    Peng, Peng
    CANCER RESEARCH, 2023, 83 (08)
  • [10] Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study
    Rodon, Jordi
    Damian, Silvia
    Furqan, Muhammad
    Garcia-Donas, Jesus
    Imai, Hiroo
    Italiano, Antoine
    Spanggaard, Iben
    Ueno, Makoto
    Yokota, Tomoya
    Veronese, Luisa
    Oliveira, Natalia
    Li, Xin
    Gilmartin, Aidan
    Goyal, Lipika
    CANCER RESEARCH, 2023, 83 (08)
12345